<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Candida guilliermondii - UTI PathoDB</title>
    <link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
</head>
<body class="bg-gray-50 text-gray-900">

    <header class="bg-yellow-600 text-white p-4 shadow-md">
        <h1 class="text-2xl font-bold text-center">Candida guilliermondii - UTI PathoDB</h1>
    </header>

    <main class="p-6 space-y-6 max-w-4xl mx-auto">

        <!-- Overview -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Overview</h2>
            <p>
                <strong>Candida guilliermondii</strong> is an opportunistic yeast that has been increasingly recognized as a cause of human infections, including urinary tract infections (UTIs), especially in immunocompromised patients and those with indwelling devices.
            </p>
        </section>

        <!-- Characteristics -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Characteristics</h2>
            <ul class="list-disc list-inside space-y-1">
                <li>Unicellular yeast</li>
                <li>Produces pseudohyphae but not true hyphae</li>
                <li>Environmental and human commensal organism</li>
                <li>Variable susceptibility to antifungal agents</li>
            </ul>
        </section>

        <!-- Pathogenicity -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Pathogenicity</h2>
            <p>
                Candida guilliermondii is associated with bloodstream infections, UTIs, and infections in patients with prosthetic devices. Its ability to adhere to surfaces and form biofilms enhances its virulence in hospital settings.
            </p>
        </section>

        <!-- Clinical Significance -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Clinical Significance</h2>
            <p>
                UTIs caused by C. guilliermondii are more common in patients with prolonged catheterization and immunosuppression. The species shows variable resistance to antifungal agents, notably azoles, necessitating susceptibility testing to guide treatment.
            </p>
        </section>

        <!-- Treatment -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Treatment</h2>
            <p>
                Antifungal therapy includes amphotericin B, echinocandins, and sometimes azoles, though resistance patterns should be checked. Device removal or replacement may be necessary for effective management of catheter-associated UTIs.
            </p>
        </section>

        <!-- References -->
        <section>
            <h2 class="text-xl font-semibold mb-2">References</h2>
            <ul class="list-decimal list-inside space-y-1">
                <li>Krcmery V, et al. "Fungemia due to Candida guilliermondii in cancer patients." J Infect. 2002.</li>
                <li>Pfaller MA, et al. "Epidemiology of candidemia in the United States." Clin Infect Dis. 2001.</li>
            </ul>
        </section>

        <!-- Back to Home Link -->
        <div class="mt-6">
            <a href="index.html" class="text-yellow-600 hover:underline">&larr; Back to Home</a>
        </div>

    </main>

    <footer class="bg-gray-200 text-center p-4 mt-6">
        &copy; 2025 UTI PathoDB. All rights reserved.
    </footer>

</body>
</html>
